Lupin Pharmaceuticals

Lupin secured an S&P Global ESG score of 91 for 2025, highlighting strong environmental, social and governance performance relative to global peers.

In October 2025, Lupin received USFDA approval for dronedarone tablets USP for the maintenance of normal sinus rhythm in adults with non-permanent atrial fibrillation or atrial flutter, expanding its cardiovascular portfolio in the United States.

Lupin has received approval from the US Food and Drug Administration (USFDA) to market its generic HIV medications in the US. This approval enhances Lupin’s presence in the US market and strengthens its portfolio in the high-impact therapeutic area of HIV treatment.

On June 5 2024, Global pharma major Lupin Limited (Lupin) announced that its European hub entity, Lupin Atlantis Holdings SA, has completed the acquisition of two well-known brands, AaraneTM in Germany and NalcromTM in Canada and the Netherlands, along with the associated trademark rights, from Sanofi.

In January 2024, Lupin Digital Health and the American College of Cardiology introduced the world's first Digital Therapeutics Certificate for Cardiologists, aiming to enhance digital healthcare practices, unveiled at the Cardiology Society of India's Platinum Jubilee celebration in Kolkata.

In November 2023, Lupin Limited unveiled Vilfuro-G, the world's premier fixed-dose triple combination drug for managing chronic obstructive pulmonary disease (COPD), after Indian regulatory approval.

In November 2023, Lupin Limited and Zydus Lifesciences Limited announced that they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India.

In November 2023, Lupin Limited announced that it had launched the world’s first fixed-dose triple combination drug (FDC) under the brand name Vilfuro-G® for the effective management of chronic obstructive pulmonary disease (COPD) in India. 

In August 2023, Lupin announced the acquisition of diabetes brands ONDERO® and ONDERO MET®, from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), including the trademark rights associated with these brands.

In August 2023, Lupin Digital Health (LDH), India’s leading Cardiac Digital Therapeutics company, announced the launch of its newest offering, LyfeTM Digital Heart Failure Clinic in India.

In July 2023, Lupin Human Welfare & Research Foundation (LHWRF) strengthened its Desh Bandhu Jan Aarogya Sewa by flagging off its Mobile Medical Van (MMV) in Jaipur. 

Lupin Limited on May 5, 2023, announced that it has entered into a definitive agreement to acquire the entire share capital of the French pharmaceutical company, Medisol, subject to approval from the French Ministry of Economy and Finance.

Lupin Limited that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Tenofovir Alafenamide Tablets,25 mg, a generic equivalent of Vemlidy Tablets, 25 mg of Gilead Sciences, Inc.

Lupin Limited announced the launch of its new state-of-the-art Regional Reference Laboratory in Bengaluru, Karnataka on April 12, 2023, as part of the expansion of its diagnostics network. 

Lupin Diagnostics launches new regional reference laboratory in Hyderabad.

Lupin launched a fixed-dose triple drug combination to treat uncontrolled asthma.

Lupin gets USFDA nod for generic version of Robinul Injection

Lupin gets tentative approval from USFDA for generic equivalent of HIV treatment drug.

Lupin launches digital therapeutics solution LYFE for heart patients.

Lupin gets US FDA nod for generic medicine to treat heart ailments.

Lupin gets USFDA nod for generic drug to treat bladder problems

In October 2022, Lupin signed an agreement to acquire two inhalation brands from Sunovion Pharmaceuticals Inc.

In June 2022, Lupin announced the launch of Lupin Diagnostics, its first Regional Reference Laboratory in Patna, Bihar.

Lupin Limited (Lupin) announced that the United States Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA), Vigabatrin.

In September 2021, TB Alliance, a non-profit drug developer, granted Lupin Limited (Lupin) a non-exclusive licence to produce pretomanid, an anti-TB medicine that is part of the three-drug ‘BPal’ regimen. Lupin plans to market the anti-tuberculosis (TB) drug in more than 140 countries including the world's top TB-burdened regions.

In June 2021, the company’s board of directors approved a proposal to enter the digital healthcare space in India. It incorporated Lupin Digital Health Ltd., a wholly owned subsidiary, to provide a digital therapeutics platform for medical practitioners and patients in the country.

In May 2021, Lupin entered a royalty-free, non-exclusive licensing agreement with Eli Lilly and Company for expanding access to the COVID-19 drug, Baricitinib. The company will now manufacture and distribute the drug in India.

In March 2021, Lupin and JIFFY.ai, an automation start-up, joined forces to expand Lupin’s automation initiatives.

Lupin launched ‘Tacrolimus’ capsules USP, 0.5 mg, 1 mg, and 5 mg, after its partner, Concord Biotech Limited (Concord), received an approval for ANDA (Abbreviated New Drug Application) from the United States Food and Drug Administration 

Lupin launched Favipiravir under the drug name ‘Covihalt’ for the treatment of patients with mild to moderate Covid-19 symptoms. This medicine is available at Rs. 49 (US$ 0.66)/ tablet in India. 

Lupin launched the generic version of Bausch Health's Apriso, used in the treatment of ulcerative colitis, in the US market

Lupin launched Adhero, a first-of-its-kind connected Smart Device in India to support treatment of Respiratory Disease

Received approval for its propranolol Hydrochloride Extended-Release (ER) capsules from Health Canada

Lupin’s subsidiary in South Africa declared commercial agreement with Creso Pharma

Nagpur facility won ENR Global Best Project Award

Launched Doxercalciferol Injection, 4 mcg/2 ml multidose vials, for the treatments of secondary hyperparathyroidism in adult patients with CKD on dialysis

Entered over the counter (OTC) market with launch of Softovac in India

Acquired US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc.

Became fifth largest generic player in the US

Commenced US Brands Business with the launch of Suprax

More than 100 patent filings

Lupin Laboratories Ltd. and Lupin Chemicals Ltd. raise money through IPOs

Joint venture in Thailand and Lupin Chemicals (Thailand) Ltd was formed

Commissioned first Formulations plant and an R&D centre at Aurangabad, Maharashtra

Commenced business